IBS Patients' Treatment Expectancy and Motivation Impacts Quality of the Therapeutic Alliance With Provider: Results of the IBS Outcome Study
In the absence of a satisfactory medical or dietary treatment, the quality of the therapeutic alliance between irritable bowel syndrome (IBS) patients and their provider is deemed critical to managing refractory IBS. Surprisingly, little research has been conducted on the nature of the therapeutic a...
Uložené v:
| Vydané v: | Journal of clinical gastroenterology Ročník 55; číslo 5; s. 411 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.05.2021
|
| Predmet: | |
| ISSN: | 1539-2031, 1539-2031 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | In the absence of a satisfactory medical or dietary treatment, the quality of the therapeutic alliance between irritable bowel syndrome (IBS) patients and their provider is deemed critical to managing refractory IBS. Surprisingly, little research has been conducted on the nature of the therapeutic alliance, factors that influence it, or practical strategies to improve it. This study sought to identify actionable variables that impact therapeutic alliance in patients with refractory IBS.
Subjects included a total of 436 Rome III-diagnosed IBS patients (80% female, mean age=41.39 y) who completed a battery of clinical measures at the beginning of the acute treatment phase of an National Institutes of Health (NIH) behavioral trial. Pretreatment candidate predictor variables were organized into 4 categories: sociodemographic, extraintestinal, interpersonal, clinical (eg, symptom severity, pain intensity), cognitive (eg, treatment motivation, expectancy for improvement). Alliance was assessed by patient and clinician-rated measures of the Working Alliance Inventory after first treatment session.
Patient reports of alliance were most strongly and consistently predicted by patient access to interpersonal support [β=0.16; 95% confidence interval (CI)=0.07-0.25], motivation for IBS symptom improvement (β=0.12; 95% CI=0.02-0.21), and expectancy of IBS symptom improvement (β=0.35; 95% CI=0.25-0.44). Therapist ratings of alliance also were predicted by patient expectancy of IBS symptom improvement (β=0.16; 95% CI=0.05-0.26).
When managing IBS, a focus on dynamic factors of treatment motivation, social support, and treatment expectancy may be useful in improving the quality of the therapeutic alliance between patient and clinical gastroenterologist. |
|---|---|
| AbstractList | In the absence of a satisfactory medical or dietary treatment, the quality of the therapeutic alliance between irritable bowel syndrome (IBS) patients and their provider is deemed critical to managing refractory IBS. Surprisingly, little research has been conducted on the nature of the therapeutic alliance, factors that influence it, or practical strategies to improve it. This study sought to identify actionable variables that impact therapeutic alliance in patients with refractory IBS.
Subjects included a total of 436 Rome III-diagnosed IBS patients (80% female, mean age=41.39 y) who completed a battery of clinical measures at the beginning of the acute treatment phase of an National Institutes of Health (NIH) behavioral trial. Pretreatment candidate predictor variables were organized into 4 categories: sociodemographic, extraintestinal, interpersonal, clinical (eg, symptom severity, pain intensity), cognitive (eg, treatment motivation, expectancy for improvement). Alliance was assessed by patient and clinician-rated measures of the Working Alliance Inventory after first treatment session.
Patient reports of alliance were most strongly and consistently predicted by patient access to interpersonal support [β=0.16; 95% confidence interval (CI)=0.07-0.25], motivation for IBS symptom improvement (β=0.12; 95% CI=0.02-0.21), and expectancy of IBS symptom improvement (β=0.35; 95% CI=0.25-0.44). Therapist ratings of alliance also were predicted by patient expectancy of IBS symptom improvement (β=0.16; 95% CI=0.05-0.26).
When managing IBS, a focus on dynamic factors of treatment motivation, social support, and treatment expectancy may be useful in improving the quality of the therapeutic alliance between patient and clinical gastroenterologist. In the absence of a satisfactory medical or dietary treatment, the quality of the therapeutic alliance between irritable bowel syndrome (IBS) patients and their provider is deemed critical to managing refractory IBS. Surprisingly, little research has been conducted on the nature of the therapeutic alliance, factors that influence it, or practical strategies to improve it. This study sought to identify actionable variables that impact therapeutic alliance in patients with refractory IBS.BACKGROUNDIn the absence of a satisfactory medical or dietary treatment, the quality of the therapeutic alliance between irritable bowel syndrome (IBS) patients and their provider is deemed critical to managing refractory IBS. Surprisingly, little research has been conducted on the nature of the therapeutic alliance, factors that influence it, or practical strategies to improve it. This study sought to identify actionable variables that impact therapeutic alliance in patients with refractory IBS.Subjects included a total of 436 Rome III-diagnosed IBS patients (80% female, mean age=41.39 y) who completed a battery of clinical measures at the beginning of the acute treatment phase of an National Institutes of Health (NIH) behavioral trial. Pretreatment candidate predictor variables were organized into 4 categories: sociodemographic, extraintestinal, interpersonal, clinical (eg, symptom severity, pain intensity), cognitive (eg, treatment motivation, expectancy for improvement). Alliance was assessed by patient and clinician-rated measures of the Working Alliance Inventory after first treatment session.METHODSSubjects included a total of 436 Rome III-diagnosed IBS patients (80% female, mean age=41.39 y) who completed a battery of clinical measures at the beginning of the acute treatment phase of an National Institutes of Health (NIH) behavioral trial. Pretreatment candidate predictor variables were organized into 4 categories: sociodemographic, extraintestinal, interpersonal, clinical (eg, symptom severity, pain intensity), cognitive (eg, treatment motivation, expectancy for improvement). Alliance was assessed by patient and clinician-rated measures of the Working Alliance Inventory after first treatment session.Patient reports of alliance were most strongly and consistently predicted by patient access to interpersonal support [β=0.16; 95% confidence interval (CI)=0.07-0.25], motivation for IBS symptom improvement (β=0.12; 95% CI=0.02-0.21), and expectancy of IBS symptom improvement (β=0.35; 95% CI=0.25-0.44). Therapist ratings of alliance also were predicted by patient expectancy of IBS symptom improvement (β=0.16; 95% CI=0.05-0.26).RESULTSPatient reports of alliance were most strongly and consistently predicted by patient access to interpersonal support [β=0.16; 95% confidence interval (CI)=0.07-0.25], motivation for IBS symptom improvement (β=0.12; 95% CI=0.02-0.21), and expectancy of IBS symptom improvement (β=0.35; 95% CI=0.25-0.44). Therapist ratings of alliance also were predicted by patient expectancy of IBS symptom improvement (β=0.16; 95% CI=0.05-0.26).When managing IBS, a focus on dynamic factors of treatment motivation, social support, and treatment expectancy may be useful in improving the quality of the therapeutic alliance between patient and clinical gastroenterologist.CONCLUSIONWhen managing IBS, a focus on dynamic factors of treatment motivation, social support, and treatment expectancy may be useful in improving the quality of the therapeutic alliance between patient and clinical gastroenterologist. |
| Author | Quigley, Brian M Vargovich, Alison M Lackner, Jeffrey M Radziwon, Christopher D |
| Author_xml | – sequence: 1 givenname: Jeffrey M surname: Lackner fullname: Lackner, Jeffrey M organization: Department of Medicine, Division of Behavioral Medicine, Jacobs School of Medicine, University at Buffalo, Buffalo, NY – sequence: 2 givenname: Brian M surname: Quigley fullname: Quigley, Brian M – sequence: 3 givenname: Christopher D surname: Radziwon fullname: Radziwon, Christopher D – sequence: 4 givenname: Alison M surname: Vargovich fullname: Vargovich, Alison M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32301832$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1PAjEQhhuDkQ_9B8b0phew7RR21xsSRBIIKBiPm253NtTsl9sukR_hf3aNmDCXeQ_PM5O8XdLKixwJueZswFng3S8nswE7GQ4SzkiHDyHoCwa8dZLbpGvtR8N4APyCtEEA4z6IDvmeP27oWjmDubO3dFuhclmT6fSrRO1Urg9U5TFdFs7sG6zI6TwrlXaWvtQqNe5Ai4S6HdLtDitVYu2MpuM0NY2K9N24HV1Xxd7EWD3QV7R12qhH5ff3qna6yJBuXB0fLsl5olKLV8fdI29P0-3kub9YzeaT8aKvJfO8PkrgkssE_NEIkPsJ8_RQ66EvheRCMhVjgn6kmR_EgfKGAkAxHyMZjWTMGYgeufu7W1bFZ43WhZmxGtNU5VjUNhQQ8MDj4LEGvTmidZRhHJaVyVR1CP8rFD9FVnWl |
| CitedBy_id | crossref_primary_10_1177_17562848221114558 crossref_primary_10_1053_j_gastro_2024_04_027 crossref_primary_10_1080_00207284_2023_2189596 crossref_primary_10_1016_j_brat_2022_104063 crossref_primary_10_1007_s10608_023_10383_8 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/MCG.0000000000001343 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1539-2031 |
| ExternalDocumentID | 32301832 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: U01 DK077738 – fundername: NIDDK NIH HHS grantid: R01 DK128927 |
| GroupedDBID | --- .-D .3C .GJ .XZ .Z2 0R~ 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 8L- AAAAV AAHPQ AAIQE AAMTA AAQQT AARTV AASCR AAUEB AAWTL AAYEP ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACNWC ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFFNX AFSOK AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI L-C L7B N9A NPM N~M O9- OAG OAH OCUKA ODA OJAPA OL1 OLG OLV OLW OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ RXW S4R S4S T8P TAF TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM YFH YOC ZFV ZGI ZXP ZZMQN 7X8 ABPXF ABZZY ACBKD ACDOF ADKSD AFBFQ AFMBP AOQMC |
| ID | FETCH-LOGICAL-c4077-e431414f38663e18f07c5cc584241240adefe8bc089d9a75233a08eb4b64d1032 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00004836-202105000-00007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1539-2031 |
| IngestDate | Sun Nov 09 13:18:46 EST 2025 Wed Feb 19 02:04:04 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4077-e431414f38663e18f07c5cc584241240adefe8bc089d9a75233a08eb4b64d1032 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 32301832 |
| PQID | 2391971370 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2391971370 pubmed_primary_32301832 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-May/June-01 |
| PublicationDateYYYYMMDD | 2021-05-01 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-May/June-01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical gastroenterology |
| PublicationTitleAlternate | J Clin Gastroenterol |
| PublicationYear | 2021 |
| SSID | ssj0017331 |
| Score | 2.352788 |
| Snippet | In the absence of a satisfactory medical or dietary treatment, the quality of the therapeutic alliance between irritable bowel syndrome (IBS) patients and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 411 |
| SubjectTerms | Adult Female Humans Irritable Bowel Syndrome - therapy Male Motivation Outcome Assessment, Health Care Quality of Life Therapeutic Alliance Treatment Outcome |
| Title | IBS Patients' Treatment Expectancy and Motivation Impacts Quality of the Therapeutic Alliance With Provider: Results of the IBS Outcome Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32301832 https://www.proquest.com/docview/2391971370 |
| Volume | 55 |
| WOSCitedRecordID | wos00004836-202105000-00007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--3w9GEDwV26ZuEi-i4gvcddFV97bkiQvSVbsr-CP8z07arHsSBHvobUibTCbfZGa-IWRP4lJqE7tIWnUY4QkhIpEqdFyV1NI4Y-OSienxhjUavN0WzXDhVoS0yqFNLA216Wl_R36QUpEI9KhYfPz6FvmuUT66GlpojJNJilDGazVrj6IIoR8hbmqB2kCTYemcYAf1s8uKujA8CfV1O7-BzPKwuZj772fOk9kAM-Gk0osFMmbzRTJdD4H0JfJ1fXoPzYpTtdiH1jDdHDz1se57kwsyN1D_aX8G12U9ZQEV68Yn9BwgeITWqIALTvzdDWoRPHX7z9AMRX5HcGeLwQuKBhE_9u2gjz9kwecxfi6Th4vz1tlVFDozRBodQBZZhB1ZkjnKEbDYhLuY6UOtEcykvpt1LI11lisdc2GEZOjsUhlzqzJVy4yn8FshE3kvt2sEUuq4Uswwp3jmalwlNWtd6qhJVWKFXCe7w4nuoOb7cIbMbW9QdEZTvU5Wq9XqvFYUHR2KnpU3Vht_kN4kM6lPVCmzGLfIpMN9b7fJlP7od4v3nVKl8N1o1r8Bd87WcA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IBS+Patients%27+Treatment+Expectancy+and+Motivation+Impacts+Quality+of+the+Therapeutic+Alliance+With+Provider%3A+Results+of+the+IBS+Outcome+Study&rft.jtitle=Journal+of+clinical+gastroenterology&rft.au=Lackner%2C+Jeffrey+M&rft.au=Quigley%2C+Brian+M&rft.au=Radziwon%2C+Christopher+D&rft.au=Vargovich%2C+Alison+M&rft.date=2021-05-01&rft.issn=1539-2031&rft.eissn=1539-2031&rft.volume=55&rft.issue=5&rft.spage=411&rft_id=info:doi/10.1097%2FMCG.0000000000001343&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1539-2031&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1539-2031&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1539-2031&client=summon |